A5047799577- Multiple Sclerosis Research Studies
- Autoimmune and Inflammatory Disorders Research
- Health Systems, Economic Evaluations, Quality of Life
- Acute Lymphoblastic Leukemia research
- Trigeminal Neuralgia and Treatments
- Rheumatoid Arthritis Research and Therapies
- Peripheral Neuropathies and Disorders
- Migraine and Headache Studies
- Fungal Plant Pathogen Control
- Chronic Myeloid Leukemia Treatments
- Veterinary medicine and infectious diseases
- Immunotherapy and Immune Responses
- Pharmaceutical Economics and Policy
- Powdery Mildew Fungal Diseases
- Infectious Diseases and Mycology
- Viral Infections and Immunology Research
- Mycobacterium research and diagnosis
- Pediatric health and respiratory diseases
- Retinal Diseases and Treatments
- Acute Myeloid Leukemia Research
- Sympathectomy and Hyperhidrosis Treatments
- Childhood Cancer Survivors' Quality of Life
- Botulinum Toxin and Related Neurological Disorders
- Phytochemistry and Bioactive Compounds
- Psychosomatic Disorders and Their Treatments
Novartis (Ireland)
2022-2023
Novartis (India)
2018-2021
Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies.
The study aim was to evaluate the cost effectiveness and budget impact of siponimod compared interferon beta-1a for adult patients with secondary progressive multiple sclerosis (SPMS) active disease, from a Swiss health insurance perspective. We conducted an analysis using Markov cohort model cycle length 1 year, life-long time horizon, discount rate 3% outcomes. used matching-adjusted indirect comparison estimate clinical outcomes data EXPAND randomised controlled trial vs placebo Nordic...
Identification of the phenotypic transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive (SPMS) is often delayed due disease complexity and an unwillingness withdraw RRMS disease-modifying therapies (DMTs), driven by limited SPMS treatment options. Despite paucity clinical evidence for efficacy in patients with SPMS, DMTs licensed are frequently continued into early stages SPMS. The cost-effectiveness oral siponimod, active DMT, versus or infused was...
Aim: The costs and consequences of initial delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease Canada. Materials & methods: A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined as first-line versus 3 5 years following switch from commonly therapies. Results: Ofatumumab resulted improvements clinical outcomes (relapses progression) productivity (employment full-time work),...
To evaluate the impact of early (at first-line) vs delayed (3-year delay) ofatumumab initiation and long-term clinical, societal, economic outcomes teriflunomide in relapsing multiple sclerosis (RMS) patients from a Spanish societal perspective.A cost-consequence analysis was conducted using an Expanded Disability Status Scale (EDSS)-based Markov model. Inputs were sourced ASCLEPIOS I II trials published literature.At end 10 years, compared with first-line treatment, projected to result...
To evaluate the cost-effectiveness of fingolimod versus interferon (IFN)-β1a at a dose 30 μg per week for treatment relapsing pediatric-onset multiple sclerosis (POMS) in Canada.A discrete-time Markov model was developed to compare with IFN β-1a over time horizon two years representing patients followed up mean age 18 from Canadian health care system perspective. Twenty-one states based on Expanded Disability Status Scale (EDSS) were considered: EDSS 0‒9 (MS), secondary progressive MS, and...
To assess disease related factors influencing the health quality of life (HRQoL) in patients with secondary progressive multiple sclerosis (SPMS) from EXPAND trial. is multicentre, double-blind, phase 3 placebo controlled trial including 1,651 participants (39.9% males) mean age 48 years 1,105 SPMS receiving siponimod treatment and 546 placebo. Various patient specific parameters, Expanded Disability Status Scale (EDSS) to disability, EuroQoL 5-dimension three level (EQ-5D-3L) HRQoL Symbol...
May 5, 2019April 9, 2019Free AccessCost effectiveness of Fingolimod Compared to Interferon-β1a in the Management Pediatric-Onset Multiple Sclerosis (POMS) Canada (P1.2-106)Hamid Reza Nakhaipour, Umakanth Vudumula, Nagasuman Toram, Vivek Khurana, Robyn Schecter, Daniela Pohl, and Nicholas AdlardAuthors Info & AffiliationsApril 2019 issue92 (15_supplement)https://doi.org/10.1212/WNL.92.15_supplement.P1.2-106 Letters Editor